spec sheet5 rows
ABT-126 was AbbVie's (formerly Abbott's) selective alpha7 nicotinic acetylcholine receptor agonist, developed for both cognitive impairment in schizophrenia and Alzheimer's disease. The alpha7 receptor is heavily expressed on hippocampal and prefrontal circuits involved in learning and attention, and it was a hot target through the 2010s after epidemiological observations tied smoking to modest cognitive benefits in schizophrenia patients. A Phase 2 trial found a real procognitive signal, but only in nonsmokers; smokers, whose alpha7 receptors were presumably already saturated or desensitized by nicotine, showed nothing. A larger Phase 2b confirmatory trial in nonsmokers, and a separate one in smokers, both failed to show meaningful benefit, and AbbVie discontinued the program around 2016 along with much of the industry's broader retreat from alpha7 agonists.
- improved composite cognitive scores in nonsmoking schizophrenia patients in an early trial
- targeted a receptor with a plausible mechanistic link to attention and memory circuits
- generally well tolerated across trials
- no benefit at all in smokers, splitting the eligible patient population
- gastrointestinal complaints reported in some trial arms
- The alpha7 nicotinic receptor field saw a wave of pharma candidates (ABT-126, TC-5619, AQW051, encenicline) all chase the same smoking-and-schizophrenia epidemiological clue in the 2010s, and nearly all of them failed to confirm in later-phase trials.
Mechanism
Selective alpha7 receptor ; intended to enhance hippocampal and prefrontal cholinergic signaling implicated in learning and attention circuits.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Dizziness, diarrhoea and fatigue were the most frequent complaints in the twelve-week schizophrenia trial, each in fewer than 8 percent of patients, and in the follow-up study in smokers the only event that separated from placebo was constipation, at 5.8 percent against none. Across both trials the adverse event profile essentially matched placebo, which is why the programme stopped for lack of effect rather than for safety. Nothing longer than about six months of exposure was ever studied.
History
Developed by Abbott/AbbVie; initial Phase 2 in nonsmoking schizophrenia patients (2016) showed a procognitive signal, but confirmatory Phase 2b trials in both nonsmokers and smokers failed to replicate benefit, and the program was discontinued.
Subjective profileweighing the evidence above
Another well-reasoned alpha7 nicotinic candidate that looked good in an early trial and evaporated on a bigger one.
Resources
This entry is here for reference.
Research
- 1.A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
- 2.Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Why did ABT-126 only work in nonsmokers?
Researchers suspect chronic nicotine exposure in smokers desensitizes or downregulates alpha7 nicotinic receptors, blunting the added effect of a selective alpha7 agonist on top of it.
Was ABT-126 ever approved for Alzheimer's instead?
No. It was tested for Alzheimer's disease cognitive impairment as well as schizophrenia, and both programs were discontinued after disappointing confirmatory trials.
Limitations of the evidence
- confirmatory Phase 2b trial failed to replicate the initial signal
Adverse effects
- no benefit at all in smokers, splitting the eligible patient population
- gastrointestinal complaints reported in some trial arms